Other Clinical Trial - TruGraf® Long-term Clinical Outcomes Study

Status Recruiting

Clinical Trial Summary

This is a prospective, multi-center, observational study. Subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at study enrollment and thereafter every 3 months. In addition subjects will have OmniGraf™ (TruGraf® and TRAC™) testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.

Clinical Trial Description

Several studies have validated TruGraf® in stable renal transplant patients to rule out subclinical acute rejection. These studies generally evaluated the diagnostic value of TruGraf® at single timepoints. Thus the value of serial monitoring and changes over time has not been previously investigated. In addition, no study has assessed TruGraf® and TRAC™in a serial and longitudinal fashion. Therefore the aim of this study is to evaluate the impact of serial monitoring renal transplant patients with both TruGraf® and TRAC™ on long term outcomes. ;

Study Design

Related Conditions & MeSH terms

Kidney Transplant Rejection

Clinical Trial Details

NCT number	NCT04491552
Study type	Observational
Source	Transplant Genomics, Inc.
Contact	Isioma Agboli, MD
Phone	510-767-8609
Email	isiomaagboli@eurofins-tgi.com
Status	Recruiting
Phase
Start date	September 9, 2020
Completion date	November 2023

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04560582` - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Completed	`NCT05747274` - SRDK0921_ Analytical Performance Study
Not yet recruiting	`NCT05482100` - CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
Recruiting	`NCT06243289` - Improving KIdney Transplantation With Cellular Therapy Study
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed	`NCT04367610` - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Enrolling by invitation	`NCT06126380` - Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients	Phase 2
Terminated	`NCT05747053` - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Active, not recruiting	`NCT03714113` - Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients	N/A
Recruiting	`NCT04091984` - The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
Recruiting	`NCT05335538` - TruGraf and TRAC In Pediatrics Study
Completed	`NCT03663335` - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients	Phase 2
Completed	`NCT03652402` - Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
Recruiting	`NCT04773392` - Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR	Phase 4
Completed	`NCT03873623` - The TOGETHER Project - Kidney
Terminated	`NCT02974686` - Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation	Phase 4
Terminated	`NCT04156204` - Immunosuppressant Medication Dosed Daily After Kidney Transplant	Early Phase 1
Completed	`NCT04601155` - Transition of Renal Patients Using AlloSure Into Community Kidney Care
Completed	`NCT03874299` - The TOGETHER Project - Kidney RNA-seq Validation
Completed	`NCT03965559` - The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant